Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their ...

A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...

A pharmacogenetics score may help physicians predict which patients with acute myeloid leukemia are more likely to respond to ...

Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

Although treatment with high-dose corticosteroids can reduce mast burden and improve symptoms such as pain, congestive heart failure, and cytopenia in patients with MCL, their effects are frequently ...